Healthcare provider profile · identity verified

Hugh Yang, D.O

Family Practice · FRESNO, CA · NPI 1801050943

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	756	197
Lisinopril	Lisinopril	496	122
Metformin Hcl	Metformin Hcl	284	79
Amlodipine Besylate	Amlodipine Besylate	265	69
Jardiance	Empagliflozin	211	46
Famotidine	Famotidine	182	39
Tamsulosin Hcl	Tamsulosin Hcl	157	45
Janumet Xr	Sitagliptin Phos/Metformin Hcl	154	36
Gabapentin	Gabapentin	149	29
Hydrochlorothiazide	Hydrochlorothiazide	124	34
Levothyroxine Sodium	Levothyroxine Sodium	121	32
Losartan Potassium	Losartan Potassium	121	32
Ibuprofen	Ibuprofen	101	38
Pioglitazone Hcl	Pioglitazone Hcl	89	23
Finasteride	Finasteride	88	17
Fluticasone Propionate	Fluticasone Propionate	85	28
Ventolin Hfa	Albuterol Sulfate	82	14
Chlorthalidone	Chlorthalidone	69	20
Metoprolol Succinate	Metoprolol Succinate	69	19
Ozempic	Semaglutide	65	suppressed
Sertraline Hcl	Sertraline Hcl	65	suppressed
Omeprazole	Omeprazole	63	15
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	60	15
Albuterol Sulfate Hfa	Albuterol Sulfate	57	23
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	54	15
Alendronate Sodium	Alendronate Sodium	53	16
Janumet	Sitagliptin Phos/Metformin Hcl	48	11
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	45	suppressed
Tramadol Hcl	Tramadol Hcl	45	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	44	suppressed
Simvastatin	Simvastatin	44	11
Azelastine Hcl	Azelastine Hcl	43	14
Prednisone	Prednisone	42	suppressed
Carvedilol	Carvedilol	41	suppressed
Breo Ellipta	Fluticasone/Vilanterol	40	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	37	20
Ketoconazole	Ketoconazole	36	20
Diclofenac Sodium	Diclofenac Sodium	33	21
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	33	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	32	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	31	suppressed
Ezetimibe	Ezetimibe	29	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	29	suppressed
Baclofen	Baclofen	27	suppressed
Rosuvastatin Calcium	Rosuvastatin Calcium	27	suppressed
Shingrix	Varicella-Zoster Ge/As01b/Pf	26	25
Glipizide Er	Glipizide	25	suppressed
Naproxen	Naproxen	25	suppressed
Glimepiride	Glimepiride	24	suppressed
Warfarin Sodium	Warfarin Sodium	24	suppressed
Meclizine Hcl	Meclizine Hcl	23	11
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	22	suppressed
Propranolol Hcl	Propranolol Hcl	21	suppressed
Allopurinol	Allopurinol	20	suppressed
Valsartan	Valsartan	20	suppressed
Glipizide-Metformin	Glipizide/Metformin Hcl	18	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	18	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	17	suppressed
Trulicity	Dulaglutide	17	suppressed
Digoxin	Digoxin	16	suppressed
Invokana	Canagliflozin	16	suppressed
Trueplus Pen Needle	Pen Needle, Diabetic	16	11
Colchicine	Colchicine	15	suppressed
Enalapril Maleate	Enalapril Maleate	15	suppressed
Nifedipine Er	Nifedipine	15	suppressed
Carbidopa-Levodopa	Carbidopa/Levodopa	14	suppressed
Cephalexin	Cephalexin	14	13
Furosemide	Furosemide	14	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	14	suppressed
Spiriva Handihaler	Tiotropium Bromide	14	suppressed
Lorazepam	Lorazepam	13	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	13	suppressed
Acarbose	Acarbose	12	suppressed
Arnuity Ellipta	Fluticasone Furoate	12	suppressed
Clobetasol Propionate	Clobetasol Propionate	12	suppressed
Hydralazine Hcl	Hydralazine Hcl	12	suppressed
Mirtazapine	Mirtazapine	12	suppressed
Pantoprazole Sodium	Pantoprazole Sodium	12	suppressed
Pravastatin Sodium	Pravastatin Sodium	12	suppressed
Procto-Med Hc	Hydrocortisone	12	suppressed
Ulticare Pen Needle	Pen Needle, Diabetic	12	suppressed
Testosterone	Testosterone	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error